Teva collaborates on skin disease treatment, releases targets
Under the agreement with Royalty Pharma, the companies will jointly develop the anti-IL-15 antibody, TEV-'408, which is in a phase 1b trial for the treatment of vitiligo
Discuss the story with the TraceFeed community.
No comments yet. Be the first to add a perspective.